Reporter brief
Multi-Center, Randomized, Single Masked Phase 2 Study of Intravitreal Injections of Sirolimus in the Treatment of Geographic Atrophy Associated With Age-Related Macular Degeneration
What happened
Trial registry update: TERMINATED. No results reported in the supplied registry record.
Why it matters
Assessment pending; this report does not establish a change in evidence.
What it does NOT prove
- The study provides no evidence of efficacy, as it was halted before completion and no outcome data comparing sirolimus to sham are reported.
- Safety concerns led to early termination, but the specific adverse events are not detailed in this document.
- The early stopping means any potential benefit or harm from longer-term treatment remains unknown.
Study design and sample
Rct; Human.
50 persons with central or non-central geographic atrophy (GA) associated with age-related macular degeneration (AMD); GA in treated eye between 0.75 and 8 disk areas (DA)
- Design
- Rct
- Sample
- 50
- Journal
- National Eye Institute (NEI)</journal> </invoke>
- Published
- Dec 10, 2015
Effect size
Not recorded.
Caveats
- Assessment: Unassessed.
- Only the source material recorded on this evidence page was assessed.
Conflicts and funding
Not recorded.
Previous evidence
See the Rapamycin timeline and recorded assessment for prior evidence.
Primary source
Cancel Death charts and briefs may be reproduced editorially with attribution to CancelDeath.com. This brief is generated from the primary recorded source facts and assessment. Its review status is shown below; verify quotations against the paper before publication.